Table 2.
Incidence of adverse events by frequency (reported by more than one subject)
| Treatment group | ||||
|---|---|---|---|---|
| Placebo (n = 5) | Mavrilimumab* (n = 27) | |||
| Adverse event | No of AEs | No (%) of subjects | No of AEs | No (%) of subjects |
| Total | 13 | 4 (80) | 69 | 20 (74) |
| Nasopharyngitis | 3 | 2 (40) | 11 | 10 (37) |
| Headache | 2 | 2 (40) | 7 | 5 (19) |
| Diarrhoea | 1 | 1 (20) | 5 | 5 (19) |
| Back pain | 1 | 1 (20) | 4 | 4 (15) |
| Peripheral oedema | 0 | 0 | 3 | 3 (11) |
| Nausea | 1 | 1 (20) | 2 | 2 (7) |
| Bronchitis | 0 | 0 | 2 | 2 (7) |
| Dizziness | 0 | 0 | 2 | 2 (7) |
| Hypertension | 0 | 0 | 2 | 2 (7) |
| Pharyngolaryngeal pain | 0 | 0 | 2 | 2 (7) |
| Vomiting | 1 | 1 (20) | 1 | 1 (4) |
*
All doses. AEs were classified according to the terminology of the Medical Dictionary for Regulatory Activities (version 11).
AE, adverse event.